Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab for Unexplained Recurrent Implantation Failure
NCT05930613Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2023
- Primary completion
- Apr 2029
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 3 trial of certolizumab pegol in Recurrent Implantation Failure (RIF), sponsored by Assistance publique - Hôpitaux de Paris. Started Nov 2023; status: recruiting.
02
Drugs
certolizumab pegol
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on NCT05930613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05930613.